Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26.3M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
8.05M
-
Shares change
-
-4.66K
-
Total reported value, excl. options
-
$10.6M
-
Value change
-
-$2.39K
-
Number of buys
-
5
-
Number of sells
-
-8
-
Price
-
$1.32
Significant Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q2 2025
24 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q2 2025.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.05M shares
of 26.3M outstanding shares and own 30.59% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (2.07M shares), BML Capital Management, LLC (1.97M shares), Sanofi (1.92M shares), Merck & Co., Inc. (1.15M shares), Bruce & Co., Inc. (522K shares), Pathway Financial Advisors LLC (103K shares), PNC Financial Services Group, Inc. (65K shares), CITADEL ADVISORS LLC (51.8K shares), BNP PARIBAS FINANCIAL MARKETS (46.9K shares), and TWO SIGMA INVESTMENTS, LP (34.4K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.